Viking Therapeutics
VKTX
33 hedge funds and large institutions have $37.9M invested in Viking Therapeutics in 2017 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 7 closing their positions.
885% more capital invested
Capital invested by funds: $3.85M → $37.9M (+$34.1M)
700% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 1
214% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 7
83% more funds holding
Funds holding: 18 → 33 (+15)
11.05% more ownership
Funds ownership: 7.3% → 18.35% (+11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$5.39M |
| 2 |
SCM
Sio Capital Management
New York
|
+$3.63M |
| 3 |
Millennium Management
New York
|
+$2.04M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.88M |
| 5 |
Renaissance Technologies
New York
|
+$1.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Ascend Capital
Orinda,
California
|
-$932K |
| 2 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
-$180K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$108K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$98K |
| 5 |
VF
Virtu Financial
New York
|
-$70K |
VKTX Hedge Fund Activity: Q4 2017 in Review
33 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q4 2017, worth a combined $37.9M — up 885% from $3.85M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new VKTX positions and 7 closed out — a net gain of 15 holders — while 8 added to existing stakes and 1 trimmed.
The largest buyer was Sphera Funds Management, adding an estimated $5.39M. The largest seller was Ascend Capital, exiting entirely with an estimated $932K sold.
- 33 institutional investors held Viking Therapeutics (VKTX) as of Q4 2017, up from 18 in Q3 2017.
- Funds reported $37.9M of Viking Therapeutics stock for Q4 2017, up 885% quarter-over-quarter.
- 22 funds opened new Viking Therapeutics positions in Q4 2017 and 7 closed out, a net change of +15 holders.
- The largest Viking Therapeutics buyer in Q4 2017 was Sphera Funds Management, an estimated $5.39M added.
- The largest Viking Therapeutics seller in Q4 2017 was Ascend Capital, an estimated $932K sold.
Based on aggregated 13F filings for Q4 2017.